Complex Abdominal Aortic Aneurysm Repair With Fenestrated Stent Grafts
Launched by GUSTAVO ODERICH · Sep 4, 2013
Trial Information
Current as of August 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to treat certain types of large blood vessel bulges called aortic aneurysms, specifically those located near the kidneys or in the chest. The treatment involves using a special device called a custom-made Cook Zenith® Fenestrated AAA Endovascular Graft, which is inserted through blood vessels to repair the aneurysm without the need for major surgery. The researchers want to see how well this method works and whether it improves patients' quality of life.
To participate in the study, patients should be between the ages of 65 and 74 and have a specific kind of aortic aneurysm that is at least 5 centimeters wide or has been growing quickly. Those with certain health issues or who cannot follow the study’s requirements may not be eligible. If someone joins the trial, they can expect regular check-ups to monitor their progress and health after the procedure. This trial is currently recruiting participants, and it aims to provide valuable insights into improving treatment for these serious conditions.
Gender
ALL
Eligibility criteria
- • General Inclusion Criteria
- * A patient may be included in the study if the patient has at least one of the following and is appropriate for treatment with a custom-made Zenith® Fenestrated AAA Endovascular Graft:
- • Juxtarenal, suprarenal or type IV thoracoabdominal aortic aneurysm with a diameter ≥ 5.0 cm or 2 times the normal aortic diameter
- • Aneurysm with a history of growth ≥ 0.5 cm per year
- • Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation.
- • General Exclusion Criteria
- • Less than 18 years of age
- • Unwilling to comply with the follow-up schedule
- • Inability or refusal to give informed consent by the patient or a legally authorized representative
- • Pregnant or breastfeeding
- • Life expectancy \< 2-years
- • Additional medical restrictions as specified in the Clinical Investigation Plan
- • Additional anatomical restrictions as specified in the Clinical Investigation Plan
About Gustavo Oderich
Gustavo Oderich is a distinguished clinical trial sponsor dedicated to advancing medical research and enhancing patient care through innovative clinical studies. With a focus on developing cutting-edge therapies, Mr. Oderich emphasizes rigorous scientific methodologies and ethical standards to ensure the integrity and reliability of trial outcomes. His commitment to collaboration with leading healthcare professionals and institutions fosters an environment of excellence, driving forward the discovery of new treatments while prioritizing patient safety and well-being. Through strategic partnerships and a patient-centered approach, Gustavo Oderich aims to contribute significantly to the medical community and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Houston, Texas, United States
Patients applied
Trial Officials
Gustavo Oderich, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials